Global insurtech funding reached $1.63bn in the first quarter of 2026, according to Gallagher Re’s Q1 2026 Global InsurTech Report. Set against the $1.67bn logged in the previous quarter, it barely moved. That flat line is the story.
Gallagher Re says Q4 2025 and Q1 2026 rank as the two strongest consecutive quarters for the sector since late 2022, after nearly three years of subdued cheques. The natural read is that the disruption trade is back on. It is not.
The recovery is real, but it is not the disruption trade
The first insurtech wave was sold as an assault on incumbents. New digital carriers, a promise to underprice and out-experience the old balance sheets. Money followed the pitch. Global insurtech funding hit an all-time high of $15.4bn across 566 deals in 2021, on CB Insights’ numbers, before collapsing to roughly $4bn by 2023.
Most of the disruption did not arrive. Lemonade, the flagship of that cohort and founded in 2015, still reported a net loss of $202m for 2024, narrower than the $237m it lost in 2023 but a loss all the same. It reached its first cash-flow-positive year in 2024, nine years after launch. That is the scoreboard for the pure D2C bet: survivable and slow, and nothing like the rout of the incumbents it was funded to deliver.
So the money coming back has watched the first wave grind. Put the insurtech funding 2026 numbers next to the 2021 peak and the level tells you as much as the direction.
The arithmetic is blunt. Run the Q1 2026 total forward at $1.63bn a quarter and the sector is on track for roughly $6.5bn across the year, still around 58% below the $15.4bn record set in 2021. Capital has returned, but not to the volume or risk appetite of the boom. It is going somewhere more disciplined.
Where the money actually went
Almost all of it went to one label. AI-focused companies took 95.2% of the quarter’s funding, raising $1.55bn across 68 deals, with every one of the ten largest rounds going to an AI-led business, Reinsurance News reported from the Gallagher Re data. Deal sizes rose 23.3% quarter-on-quarter.
Life and health insurtech funding nearly doubled to $718.99m. Insurtechs working on AI liability and cyber cover drew more than $440m, as Gallagher Re’s report tracks the two risk classes converging around the exposures created by digital delegation.
Those categories show AI doing an unglamorous job: underwriting, pricing, claims triage, product configuration, and the risk AI itself now creates inside a book. This is not software built to replace insurers. It is software built to be bought by them.
Why incumbents are the customer now
Established carriers across the US, the UK and Europe face pressure to adopt AI, cut cost and launch products faster while running on core systems that predate the cloud. Most cannot bolt a model onto a mainframe policy engine and call it modernisation.
That gap is the market. A carrier that wants to reprice a product, launch a new line or automate a claims journey has two options: a multi-year rip-and-replace of its core platform, or a configurable layer that sits over the legacy stack and lets it move without tearing the engine out. The second option is cheaper, faster and far less likely to end a chief information officer’s career.
This is where the recurring revenue lives. An incumbent that embeds a pricing or distribution layer into a live book does not churn out next quarter; it renews, expands and pays through the cycle. That is a duller return than a consumer land-grab, and a much more bankable one.
The infrastructure thesis, in one funding round
The shape of the new money shows up cleanly in a single deal. In October 2025, the no-code insurance platform INSTANDA closed a $20m round led by CommerzVentures, taking total funding past $85m.
INSTANDA, founded the same year as Lemonade, says it now serves more than 80 tier-one insurers and MGAs across the US and UK, has grown at over 40% compound annually, and has reached profitability. Its product is policy administration and distribution plumbing that lets an established carrier configure and launch products without ripping out its core systems. The capital is earmarked for expansion across North America and Europe and for deeper data-science capability.
None of that is a consumer brand. It is a picks-and-shovels sale to the incumbents the first wave meant to displace. Tim Hardcastle, INSTANDA’s chief executive, argues that the next phase of investment will favour companies solving practical operating problems for insurers rather than those relying on an AI label alone. He is talking his own book, but the funding pattern supports the point.
The lesson is not that INSTANDA is the winner over Lemonade, both founded in 2015. It is the profile: profitable, embedded with carriers, selling modernisation to legacy rather than betting against it. That profile is what a disciplined market now underwrites.
An AI label is not a business
Here is where the 95.2% figure gets dangerous. When one word attracts almost every dollar in a sector, the word starts getting funded on its own. Some of that $1.55bn is backing genuine workflow, and some of it is backing a slide deck with three letters on it.
The insurance-specific problem is that AI has nowhere to sit. Most carriers still run on legacy policy, claims and pricing systems that were never built to host a model, govern its outputs, or feed it clean data. An AI product that cannot embed into those workflows, be audited by a regulator and connect to the systems that actually issue the policy is a demo, not a business.
That is the fault line the next 18 months will expose. The AI insurtech companies that hold their valuations will be the ones whose models are already running inside real underwriting and distribution, priced into live books, governed to a standard a compliance team will sign. The ones sold on the label alone will get repriced when buyers ask what, specifically, the model changed in the loss ratio.
The near-doubling of life and health funding to $718.99m fits the same pattern: underwriting, data and pricing machinery for a protection book, not a new consumer brand. It is a modernisation trade wearing an AI badge, and the badge is the part most likely to be mispriced.
Regulators are asking the same question from the other side. The convergence Gallagher Re flags between AI liability and cyber cover is the market pricing the downside of models embedded in critical infrastructure. If a model can create an insurable loss, its makers cannot also claim it is too novel to be governed.
What it means for fintech investors
For anyone allocating into the sector, the temptation is to treat the rebound as permission to rerun 2021. That is the trap. The funding has returned, but the thesis under it has inverted, from betting against incumbents to selling to them.
The durable returns in this cycle sit with infrastructure that a carrier will adopt, embed and pay for on renewal: underwriting and pricing engines, distribution platforms, data plumbing, and the governance layer that makes any of it usable inside a regulated book. Those companies look boring next to a D2C brand. They also have paying customers and, increasingly, profits.
Two tests separate the signal from the label. Does the product run inside an insurer’s actual workflow, or does it sit beside it as a pilot that never scales. And is there a paying incumbent on the other side of the contract, or only a funding round and a promise.
Apply those two tests to any AI insurtech pitch and most of the 95.2% sorts itself quickly. A handful are selling modernisation that a carrier will renew for a decade. The rest are selling the badge. Capital learned the cost of confusing the two the first time. The headline is a reminder that it can forget just as fast.
